Shimura, M. Et Al. 2023. Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial. JAPANESE JOURNAL OF OPHTHALMOLOGY , vol.67, no.3 , 264-279.

Shimura, M., Kitano, S., Ogata, N., Mitamura, Y., Oh, H., Ochi, H., ... Ohsawa, S.(2023). Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial. JAPANESE JOURNAL OF OPHTHALMOLOGY , vol.67, no.3, 264-279.

Shimura, Masahiko Et Al. "Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial," JAPANESE JOURNAL OF OPHTHALMOLOGY , vol.67, no.3, 264-279, 2023

Shimura, Masahiko Et Al. "Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial." JAPANESE JOURNAL OF OPHTHALMOLOGY , vol.67, no.3, pp.264-279, 2023

Shimura, M. Et Al. (2023) . "Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial." JAPANESE JOURNAL OF OPHTHALMOLOGY , vol.67, no.3, pp.264-279.

@article{article, author={Masahiko Shimura Et Al. }, title={Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial}, journal={JAPANESE JOURNAL OF OPHTHALMOLOGY}, year=2023, pages={264-279} }